Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.

Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE; Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium..

Pediatrics. 2012 Dec;130(6):1003-11. doi: 10.1542/peds.2012-0727. Epub 2012 Nov 19.

2.

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.

Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD.

J Clin Oncol. 2002 Mar 15;20(6):1677-82.

PMID:
11896119
3.

Long-term complications of therapeutic exposures in childhood: lessons learned from childhood cancer survivors.

Bhatia S.

Pediatrics. 2012 Dec;130(6):1141-3. doi: 10.1542/peds.2012-2884. Epub 2012 Nov 19. Review. No abstract available.

4.

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD.

Lancet Oncol. 2010 Oct;11(10):950-61. doi: 10.1016/S1470-2045(10)70204-7. Epub 2010 Sep 16.

5.

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.

Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdière C, Michon B, Schorin MA, Sallan SE.

J Clin Oncol. 2012 Apr 1;30(10):1042-9. doi: 10.1200/JCO.2010.30.3404. Epub 2012 Feb 27.

6.

Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.

Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A.

Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1-84. Review.

7.

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.

Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE.

J Clin Oncol. 2016 Mar 10;34(8):854-62. doi: 10.1200/JCO.2015.60.8851. Epub 2015 Dec 23.

8.

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.

Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB.

Cancer. 2013 Oct 1;119(19):3555-62. doi: 10.1002/cncr.28256. Epub 2013 Jul 16.

9.

Does anthracycline administration by infusion in children affect late cardiotoxicity?

Levitt GA, Dorup I, Sorensen K, Sullivan I.

Br J Haematol. 2004 Feb;124(4):463-8.

PMID:
14984495
10.

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD.

N Engl J Med. 1995 Jun 29;332(26):1738-43.

11.

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE.

N Engl J Med. 2004 Jul 8;351(2):145-53.

12.

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I.

J Clin Oncol. 1997 Jan;15(1):61-8.

PMID:
8996125
13.

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.

Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD.

J Clin Oncol. 2005 Apr 20;23(12):2629-36.

PMID:
15837978
14.

Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.

Amigoni M, Giannattasio C, Fraschini D, Galbiati M, Capra AC, Madotto F, Cesana F, Jankovic M, Masera G, Mancia G.

Pediatr Blood Cancer. 2010 Dec 15;55(7):1343-7. doi: 10.1002/pbc.22637.

PMID:
20589666
15.

Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.

Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE.

Klin Padiatr. 2007 May-Jun;219(3):134-8.

PMID:
17525906
16.

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP.

N Engl J Med. 1991 Mar 21;324(12):808-15.

17.

Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.

Rammeloo LA, Postma A, Sobotka-Plojhar MA, Bink-Boelkens MT, Berg A, Veerman AJ, Kamps WA.

Med Pediatr Oncol. 2000 Jul;35(1):13-9.

PMID:
10881002
18.

Exposure to anthracyclines during childhood causes cardiac injury.

Lipshultz SE.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. Review.

PMID:
16781284
19.

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JR, Lipshultz SE.

J Clin Oncol. 1998 Feb;16(2):545-50.

PMID:
9469339
20.

Supplemental Content

Support Center